M7: A novel in vitro CDK1 inhibitor suppressing colorectal cancer cell proliferation, migration and promoting apoptosis

Objective: Colorectal cancer has a high mortality rate, and drug resistance limits the efficacy of targeted therapies. This study aims to explore the role of M7 in colorectal cancer, identify its targets, and assess its potential as a therapeutic agent. Methods: A multi-stage biochemical screening s...

Full description

Saved in:
Bibliographic Details
Main Authors: Lihong Yang, Yipan Zhu, Xinyu Ding, Jing Sun, Xinyu Cao, Zhisong Zhang, Luyuan Li, Jianping Lin
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:European Journal of Medicinal Chemistry Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2772417425000275
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Colorectal cancer has a high mortality rate, and drug resistance limits the efficacy of targeted therapies. This study aims to explore the role of M7 in colorectal cancer, identify its targets, and assess its potential as a therapeutic agent. Methods: A multi-stage biochemical screening strategy combined with bio-assay validation was used. In vitro ADP-Glo™ kinase assays verified M7's activity as a potential CDK1 inhibitor. Results: M7 inhibits the proliferation and migration of HCT116 and Lovo cells by down-regulating EMT-related genes, promotes apoptosis by regulating apoptosis-related genes, and targets CDK1, causing G2/M phase arrest. Conclusions: M7, a novel CDK1 inhibitor, shows potential for colorectal cancer drug development.
ISSN:2772-4174